SpyBiotech Secures £4m in Seed Funding

SpyBiotech, an Oxford University spinout developing a molecular superglue for rapid development of vaccines targeting a range of diseases, has secured £4 million in seed funding. The round was led by Oxford Sciences Innovation, the research commercialization company of Oxford University, with participation from GV. SpyBiotech plans to use the funds to develop the technology and get its first candidates ready for Phase I trials. The company initially focuses on virus-like particles (VLPs), a technology to induce immune responses by vaccination. SpyBiotech plans to target infectious diseases including major viral infections, with a view to developing SpyVLP into a universal platform that can be adapted to target a wide variety of conditions, including future outbreaks and pandemics.

Oxford University Spinout SpyBiotech Secures £4 Million in Seed Funding

SpyBiotech, an Oxford University spinout, is developing a molecular superglue for rapid development of vaccines targeting a range of diseases. The company's technology, based on the bacterium Streptococcus pyogenes (Spy), enables the creation of stable vaccines that induce antibody responses. They initially focus on virus-like particles (VLPs), a technology to induce immune responses by vaccination. SpyBiotech plans to target infectious diseases including major viral infections, with a view to developing SpyVLP into a universal platform that can be adapted to target a wide variety of conditions, including future outbreaks and pandemics.

SpyBiotech is an Oxford University spinout developing a molecular superglue for rapid development of vaccines targeting a range of diseases.

8 years ago

Oxford University Spinout SpyBiotech Secures £4 Million in Seed Funding

ProblemBiotechnology

Solution

Covered on